Article Sidebar
Views pdf: 54
TOXICITY PROFILE OF DOCETAXEL PLUS ANDROGEN DEPRIVATION THERAPY AS FIRST-LINE TREATMENT FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD STUDY FROM HANOI ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the toxicity profile of docetaxel plus androgen deprivation therapy (ADT) as first-line treatment for metastatic hormone-sensitive prostate cancer (mHSPC) at Hanoi Oncology Hospital. Methods: A descriptive study was conducted on 40 patients with stage IV hormone-sensitive prostate cancer treated with docetaxel and ADT between January 2019 and September 2024. Toxicities were assessed according to CTCAE v5.0. Results: Common hematologic toxicities included neutropenia (60%), with 15% experiencing grade ≥3, and anemia (25%). Non-hematologic toxicities included nausea (37.5%), fatigue (35%), peripheral edema (35%), and sensory neuropathy (15%). Most adverse events were grade 1–2; only one case of febrile neutropenia grade 4 was reported. No treatment-related deaths were observed. Conclusion: The docetaxel plus ADT regimen was generally well tolerated with manageable toxicities, suggesting it is feasible in real-world clinical practice in Vietnam. Hematologic toxicities should be monitored closely to optimize patient safety.
Article Details
Keywords
mHSPC, ADT, docetaxel, toxicities
References
2. Fizazi K, Foulon S, Carles J et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomized, phase 3 study with a 2×2 factorial design. Lancet. 2022; 399(10336):1695-1707.
3. Park K, Kim IY, Park I et al. Effectiveness of adding docetaxel to androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean real-world practice. Yonsei Med J. 2023; 64(2):86-93.
4. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet. 2016; 387(10024):1163–1177.
5. Lendorf ME, Petersen PM, Svendsen AS et al. Effectiveness of docetaxel for metastatic hormone-sensitive prostate cancer in clinical practice. Eur Urol Open Sci. 2021; 24:25–33.
6. Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015; 373(8):737–746.
7. Kwon WA, Joung JY, Lee JE et al. Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: a retrospective study. Investig Clin Urol. 2019; 60(3):195–201.
8. Đỗ AT, Nguyễn Đình L. Kết quả điều trị của docetaxel trên bệnh nhân ung thư tiền liệt tuyến di căn kháng cắt tinh hoàn sau thất bại điều trị bước một với abiraterone acetate. VMJ. 2024;537(1).